

A model framework for projecting the prevalence and impact of Long-COVID in the UKA model  
framework for projecting the prevalence and impact of Long-COVID in the UK

1 *A model framework for projecting the*  
2 *prevalence and impact of Long-COVID*  
3 *in the UK*

4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

Chris Martin, Director of Modelling, Crystallise. Honorary Researcher, UCL Institute of Health Informatics.

Michiel Luteijn, Biometric Research Data Specialist at Hannover Re UK Life branch. 10 Fenchurch Street, London, EC3M 3BE.

William Letton, Research and Development Consultant, Crystallise.

Josephine Robertson, Health & Care Actuary, MPH.

Stuart McDonald, Head of Demographic Assumptions and Methodology at Lloyds Banking Group.

A model framework for projecting the prevalence and impact of Long-COVID in the UKA model  
framework for projecting the prevalence and impact of Long-COVID in the UK

## 18 Keyword list

19 Long-COVID, SARS-CoV-2, COVID-19, EQ-5D, Quality Adjusted Life Years

## 20 Abstract

### 21 Background

22 The objective of this paper is to model lost Quality Adjusted Life Years (QALYs) from symptoms arising  
23 from COVID-19 in the UK population, including symptoms of 'long-COVID'. The scope includes QALYs  
24 lost to symptoms, but not deaths, due to acute COVID-19 and long COVID.

### 25 Methods

26 The prevalence of symptomatic COVID-19, encompassing acute symptoms and long-COVID symptoms,  
27 was modelled using a decay function. Permanent injury as a result of COVID-19 infection, was  
28 modelled as a fixed prevalence. Both parts are combined to calculate QALY loss due to COVID-19  
29 symptoms.

### 30 Results

31 Assuming a 60% final attack rate for SARS-CoV-2 infection in the population, we modelled 299,719  
32 QALYs lost within 1 year of infection (90% due to symptomatic COVID-19 and 10% permanent injury)  
33 and 557,754 QALYs lost within 10 years of infection (49% due to symptomatic COVID-19 and 51% due  
34 to permanent injury). The UK Government willingness-to-pay to avoid these QALY losses would be  
35 £17.9 billion and £32.2 billion, respectively. Additionally, 90,143 people were subject to permanent  
36 injury from COVID-19 (0.14% of the population).

### 37 Conclusion

38 Given the ongoing development in information in this area, we present a model framework for  
39 calculating the health economic impacts of symptoms following SARS-CoV-2 infection. This model  
40 framework can aid in quantifying the adverse health impact of COVID-19, long COVID and permanent  
41 injury following COVID-19 in society and assist the proactive management of risk posed to health.  
42 Further research is needed using standardised measures of patient reported outcomes relevant to  
43 long COVID and applied at a population level.

## A model framework for projecting the prevalence and impact of Long-COVID in the UK model framework for projecting the prevalence and impact of Long-COVID in the UK

### 44 Introduction

45 In December 2019, a series of pneumonia cases, now known to be caused by the novel SARS-Cov-2  
46 virus, emerged in Wuhan, China (1). The novel SARS-Cov-2 virus quickly spread across the globe and  
47 on March 11<sup>th</sup>, 2020, the WHO made the assessment that COVID-19 can be characterised as a  
48 pandemic. As of April 2021, the global confirmed death toll stands at over 1.4 million, with over  
49 150,000 deaths mentioning COVID-19 on the death certificate in the UK (2,3).

50 Over the course of the COVID-19 pandemic, it has emerged that some COVID-19 patients suffer  
51 symptoms long after initial infection. The National Institute for Health and Care Excellence (NICE) has  
52 defined three phases to symptoms following COVID-19 (4). First, 'Acute COVID-19 infection' covers  
53 the period of active infection up to 4-weeks post-infection. Second, 'Ongoing symptomatic COVID-19'  
54 covers the period when infection should have ceased but persisting effects from the infection that  
55 may take time to heal may be present from 4 and 12-weeks post-infection. Third, 'Post-COVID-19  
56 syndrome' is defined as '*Signs and symptoms that develop during or following an infection consistent  
57 with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis.*'  
58 Long COVID describes both ongoing symptomatic COVID-19 as well as post-COVID-19 syndrome.  
59 Documented symptoms for long COVID include breathlessness, fatigue, myalgia, chest pains and  
60 insomnia (5).

61 Post-COVID-19 syndrome may persist long after active infection has ceased and in some cases  
62 symptoms will be permanent. Lung scarring following coronavirus related ARDS or from the high-  
63 pressure mechanical ventilation used in its treatment has been widely documented (6). In a study of  
64 patients with acute respiratory distress syndrome about a third of those who were previously  
65 employed were still unemployed 5-years later (7), suggesting long term disability. A dysfunctional and  
66 uncontrolled immune response can cause multi-organ damage, particularly the liver and kidneys, and  
67 disrupt the coagulation control mechanisms of the blood (8). This can precipitate major adverse  
68 cardiovascular events which may have long-term consequences such as heart failure or hemiplegia.  
69 Data from the COVID Infection Survey study on long-COVID suggests that the risk of major adverse  
70 cardiovascular events is about ten times higher in cases with non-intensive care hospitalized patients  
71 with COVID when compared to matched controls (9). Following treatment in critical care with acute  
72 respiratory distress syndrome, about 25% of patients have post-traumatic stress disorder and about  
73 40% suffer depression (10,11). Severe illness often results in prolonged periods of immobility which  
74 range from simple lack of exercise to prolonged bed rest, resulting in further knock-on health impacts.  
75 Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) are examples  
76 of two other coronavirus outbreaks that have caused similar symptoms to SARS-Cov-2 in the acute  
77 stage of infections (i.e., viral pneumonia and ARDS). A recent systematic review and meta-analysis that  
78 evaluated the long-term clinical outcomes after SARS and MERS suggest similar symptoms were found  
79 6 to 12-months post discharge, namely reduced lung function, reduced ability to exercise, PTSD,  
80 depression, anxiety and reduced Quality of Life scores (12).

81 The objective of this paper is to model lost Quality Adjusted Life Years (QALYs) from both acute COVID-  
82 19 and long COVID symptoms arising from COVID-19 in the UK population. The scope does not include  
83 COVID-19 deaths. The parameterisation of the model was based on a literature review. This modelling  
84 framework divides the symptomatic cohort into two groups: symptomatic COVID and COVID  
85 (permanently) injured. The symptomatic COVID group includes all three NICE defined categories  
86 described earlier. The assumption is that there are a variety of patterns of illness in the survivors with  
87 varying duration and differing aetiologies, but that all are self-limiting and will eventually recover. The  
88 COVID injured group includes people in the post-COVID-19 syndrome group that may have persisting

A model framework for projecting the prevalence and impact of Long-COVID in the UK model framework for projecting the prevalence and impact of Long-COVID in the UK

89 symptoms as a result of permanent injury following infection and associated treatment. These  
90 symptoms are assumed to be permanent for the purpose of modelling.


91 **Method**

92 **Model**

93 We modelled QALYs lost due to COVID-19 illness, but not deaths, in the UK population of 66.6 million.  
94 Our baseline model assumed a 60% attack rate at day 0 and no reinfections. Univariate sensitivity  
95 analysis was carried out on key model parameters. Symptom prevalence for the SARS-Cov-2 infected  
96 is modelled using a decay function based on the national Coronavirus Infection Survey (9). A second  
97 group, the COVID permanently injured, is kept at a fixed prevalence. Both symptomatic COVID-19  
98 cases and the permanently injured were divided into three mutually exclusive treatment groups: non-  
99 hospitalised, ward-based care and ITU care (**Figure 1**). For the symptomatic COVID-19 cases, COVID-  
100 19-related QALY loss differed by treatment group, while the probabilities of emerging with permanent  
101 injury also vary by treatment group.

102 The core of the model is a calculation of the cumulative days lived with symptoms and/or permanent  
103 injury up to the modelled time-horizon, multiplied by the number of Quality Adjusted Life Years lost  
104 per day for those with symptoms and discounted over time. The time horizon is set at the life  
105 expectancy for both the Symptomatic COVID and COVID injured cohorts. Taking account of the age  
106 distribution of people admitted with COVID-19 (13), the population weighted average life expectancy  
107 for them as of 2019 is 19.19 years (own calculations). It is expected that those admitted are in poorer  
108 health than the population average and so a reduction factor of 50% is applied to reach a time horizon  
109 of 10 years for hospitalised patients. This is in-line with Briggs et al, who estimate the life expectancy  
110 of the average UK COVID-19 death at 10.94 years (14). Model parameters, plus their sources, are  
111 summarised in **Table 1**.

112



113

114 *Figure 1. The pathways of care for the three survivor compartments amongst symptomatic patients.*

115 **Model parameters**

116 **Prevalence of symptoms**

117 UK surveys of prevalence of symptoms show a range of outcomes, with hospital-based surveys (5,15)  
118 showing higher and an app-based survey (16) showing a lower prevalence of symptoms than the  
119 national Coronavirus Infection Survey (9) (**Figure 2**). The national Coronavirus Infection Survey is  
120 considered most relevant as it contains the largest sample and provides a reference to the UK general  
121 population prevalence. The Coronavirus Infection Survey consists of a random, a-priori, selected  
122 sample that is invited for COVID tests and therefore would cover asymptomatic and symptomatic

## A model framework for projecting the prevalence and impact of Long-COVID in the UK model framework for projecting the prevalence and impact of Long-COVID in the UK

123 cases. Two key data points provide the prevalence of symptoms at 5 and 12-weeks, which were  
124 approximately 20% and 10% respectively. A natural history of symptom prevalence over time was  
125 fitted to all infections in the model by fitting an exponential decay curve on these two data points,  
126 plus a 50% symptom prevalence assumed at  $t = 0$  (Equation 1).


127 *Equation 1*

$$128 \quad P_{\text{Symptomatic COVID},t} = 0.4548 * e^{-0.132*t}$$

129 Where:

- 130 •  $P_t$  is the prevalence of any symptoms at time  $t$  in weeks following infection.
- 131 • Decay function constant = 0.4548 and rate of decay = -0.132 derived using CIS study data  
132 points.

133 Figure 2: Symptom prevalence across studies identified in the UK by duration and severity group.



134

### 135 Distribution of groups and group mortality outcomes

136 The number of UK positive tests (2,657,305) and hospital admissions (287,662) with COVID-19 up to  
137 31<sup>st</sup> October 2020 indicates 10.8% of known cases were admitted to hospital (3). We assume a similar  
138 distribution for symptomatic cases. Assuming the mortality rate in the non-hospitalised group is  
139 negligible, the surviving non-hospitalised fraction of all positive tests is 89.2%. Of those admitted to  
140 hospital (10.8%), 16.5% of these are admitted to critical care (17) leaving 9.0% of all cases who are  
141 admitted for ward-care only. The mortality rate for critical care patients was 38% in October 2020 (18)  
142 meaning 62% of the 1.8% of cases admitted to critical care survive (1.1%). As of the 31<sup>st</sup> August 2020  
143 there had been 118,613 patients admitted to hospital in England, Wales and Northern Ireland  
144 (excluding ITU). Of those, 27,483 died on the wards making the ward mortality 23.2% with 76.8%  
145 surviving (3,19). Therefore, 6.9% of the 9.0% admitted for ward-care survive.

### 146 Prevalence of permanently injured

147 The proportion of known COVID-19 cases that are permanently injured is not yet known. It is assumed  
148 that only patients with positive COVID-19 tests that had symptoms at 6 weeks post-COVID infection  
149 can get permanent injury. Based on an estimated 12% of the 66.6 million UK population having been  
150 infected (20) and 2.66 million positive COVID-19 tests (3) as of December 31<sup>st</sup>, 2020, 33% of SARS-Cov-  
151 2 infections resulted in a positive test (assuming no reinfections). Symptom prevalence at 6 weeks is

## A model framework for projecting the prevalence and impact of Long-COVID in the UKA model framework for projecting the prevalence and impact of Long-COVID in the UK

152 set at 72% for ITU and 60% for ward patients (15), while for non-hospitalised patients it is set at 16%  
153 (interpolated from the COVID Infection survey (9)).

154 About a third of previously employed patients with ARDS were still unemployed 5-years later (7). We  
155 assume that disability arising from the illness was the sole cause of unemployment and that a fraction  
156 who are injured may manage to return to work, implying an injured figure higher than 33%. Reflecting  
157 this uplift, we estimate that 50% of the ITU survivors with symptoms at 6 weeks post-COVID will be  
158 left permanently injured. For the ward-based group and the non-hospitalised group, we assume 5%  
159 permanently injured and 0.5% permanently injured amongst survivors symptomatic at 6 weeks post-  
160 COVID, respectively (10% and 1% of the ITU rate, respectively). Using the breakdown between non-  
161 hospitalised (89.2%), ward (9%) and ITU (1.8%) populations for symptomatic cases, taking into account  
162 deaths in the latter two groups, results in a weighted prevalence of 0.62% permanently injured  
163 amongst COVID-19 cases with positive tests. Adjusting for positive tests only results in a final 0.2%  
164 prevalence of the permanently injured amongst all COVID-19 cases.

### 165 Utility

166 Average loss of utility for hospitalised COVID-19 patients, split by general ward-care (-6.1%), and care  
167 on ITU treatment (-15.5%) was reported in the UK after a mean of 48 days (15). For the purpose of the  
168 model, we take the prevalence of persisting symptoms as that of the prevalence of persistent fatigue  
169 (72% for ITU patients and 60% for ward-only patients) on the assumption that the vast majority of  
170 other symptoms will co-exist with fatigue. The reported average utility change is converted into the  
171 COVID-19 symptomatic utility change using the persisting symptom prevalence. This results in a  
172 COVID-19 symptomatic utility change of  $-6.1\%/60\% = -10\%$  for ward patients and  $-15.5\%/72\% = -22\%$   
173 for ITU patients symptomatic at 48 days post COVID-19. It was not possible to source utility for a UK  
174 non-hospitalised population. We assumed the utility loss for non-hospitalised COVID-19 patients with  
175 persistent symptoms to be the same as for the ward-based patients at -10%.

176 The utility for the permanently injured group is taken from a secondary health-economic analysis of a  
177 randomised controlled trial of 795 patients ventilated in critical care in the UK (21). At one-year post-  
178 discharge, mean utility was 0.58, both for those above and below the age of 65. Taking into account  
179 the reference population utility for the UK (0.856) (22), the ARDS specific utility at 1-year is calculated  
180 at  $0.58/0.856 = 0.68$ .

181 Aggregate COVID-specific utility for the symptomatic COVID cohort was calculated at -11%, using a  
182 weighted sum of the utilities for the three treatment groups (ward, ITU and population).

A model framework for projecting the prevalence and impact of Long-COVID in the UKA model  
 framework for projecting the prevalence and impact of Long-COVID in the UK

183 Table 1: Key parameter values used in this analysis.

Parameter	Value	Source	Evidence strength	Sensitivity analysis
<b>Infection attack rate</b>	60%	Results of an age-stratified, susceptible, exposed, infected, recovered and died (SEIRD) model (own calculations).	key assumption update as risk of infection varies. Availability of testing may impact figures.	48-72%
<b>Prevalence function for prevalence of symptoms post COVID-19 by the day.</b>	$P_S = C \cdot e^{-\lambda \cdot days}$ C = 0.4548 l = 0.132	Fitted to the results of the CIS long-COVID report December 2020 (9) plus an assumed 50% symptoms at t = 0.	key assumption update as evidence emerges	Constant term 0.3638-0.5458
<b>Prevalence of symptoms at 6-weeks for survivors of ITU.</b>	72%	(15)		
<b>Prevalence of symptoms at 6-weeks in ward-care only survivors.</b>	60%	(15)		
<b>Proportion of ITU survivors with persistent symptoms at 6-weeks who are permanently injured.</b>	50%	An assumption based on the observation that 33% of those employed at the time of admission to ITU with ARDS are still unemployed 5-years later (7) with an up-lift applied to reflect those returning to work while permanently injured.	Placeholder estimate to be updated when evidence emerges	40-60%
<b>Proportion of ward-care survivors with persistent symptoms at 6-weeks who are permanently injured.</b>	5%	An assumption that the prevalence is 10% of the ITU prevalence.		
<b>Proportion of non-hospitalised cases with persistent symptoms at 6-weeks who are permanently injured.</b>	0.5%	An assumption that the prevalence is 10% of the ward-care prevalence.		
<b>Proportion of all known cases surviving critical care.</b>	1.1%	Calculated from the proportion of cases admitted to ITU and the survival rate on ITU.	Survival and hospitalisation rates may change as treatment improves, vaccine reduce disease risk, virus variants impact fatality.	
<b>Proportion of all known cases surviving ward.</b>	6.9%	Calculated from the proportion of cases admitted to a hospital ward and the survival rate on the ward.		
<b>Proportion of all known cases that are non-hospitalised that survive.</b>	89.2%	The proportion of cases not admitted on the assumption that the mortality rate is negligible in this group.		
<b>Adjusted prevalence of permanent injury for all infections, known and unknown.</b>	0.226%	Calculated from the prevalence of permanent injury in known cases and the proportion of all infections that are identified as cases.	key assumption update as evidence emerges	0.182-0.273
<b>Utility loss for all symptomatic cases</b>	0.103	Derived from weighting the average utility loss for symptomatic ward and ITU survivors at 6 weeks (15). Symptomatic non-hospitalised patients are assumed to have similar utility loss as symptomatic ward patients.		0.082-0.123
<b>Utility loss for those left with permanent injury post-COVID.</b>	0.318	Calculated from the utility loss at 1-year post ITU discharge for ARDS (21) and the population norm for England (22).	Evidence will need to be accumulated for COVID-19	0.254-0.381
<b>Time horizon (years)</b>	10	Assumption based on adjusted weighted population life expectancy for COVID-19 hospital admissions.	Key assumption update as evidence emerges.	1-20
<b>Annual discount rate for future QALYs</b>	1.5%	(23)		
<b>Monetary value per QALY</b>	£60,000	(23)		

184




## A model framework for projecting the prevalence and impact of Long-COVID in the UKA model framework for projecting the prevalence and impact of Long-COVID in the UK

### 185 Results

186 We modelled QALY loss due to COVID-19 symptoms, but not deaths. Within a 1-year time-horizon,  
187 the estimated undiscounted QALY loss in survivors was 299,719 (0.6% of the total expected QALYs  
188 for that year) with 271,027 QALYs (92%) lost to symptomatic COVID-19 in the acute, ongoing and  
189 post-COVID syndrome; and 28,692 (8%) lost to permanent injury from COVID-19 including lung  
190 fibrosis, the sequelae of major adverse cardiovascular events like heart attacks and strokes and  
191 psychological impacts such as PTSD. Discounted QALY loss was 298,932, representing a monetary  
192 value of £17.9 billion based on the UK Governments willingness-to-pay per QALY (23), and a loss of  
193 about 0.0075 QALY per infection. With a 10-year time-horizon, the estimated total undiscounted  
194 QALY loss in survivors was 557,754 with 271,300 (54%) QALYs lost to symptomatic COVID-19 in the  
195 acute, ongoing and post-COVID syndrome, 286,454 (46%) lost to permanent injury from COVID-19.  
196 Discounted QALY loss was 536,867, representing a monetary value of £32.2 billion and a loss of  
197 about 0.013 QALY per infection. Regardless of timeframe, an estimated 90,142 people would be left  
198 with permanent injury.

199 Following infection, QALY-loss due to symptomatic COVID-19 increases with time, but quickly levels  
200 off as people recover. However, for those living with permanent damage, QALY-loss accumulates over  
201 their life expectancy (Figure 3).

202 Figure 3. Cumulative QALY loss for symptomatic COVID and permanent injury due to COVID.



203


204 Sensitivity analyses were performed on parameter values in order to assess the robustness of the  
205 model over the illustrative 10-year time horizon (Figure 4). Unsurprisingly, discounted QALY loss is  
206 sensitive to the time horizon considered. However, as the majority of the QALY loss occurs in the first  
207 year, reducing the time horizon from 10 to 1-year reduced discounted QALY loss by only 44.3%. A



A model framework for projecting the prevalence and impact of Long-COVID in the UKA model  
 framework for projecting the prevalence and impact of Long-COVID in the UK

208 reduction or increase in attack rate directly translates into a similar reduction or increase in QALY loss,  
 209 while the model is less sensitive to parameters to do with QALY loss and prevalence for symptomatic  
 210 COVID-19 and permanent injury as QALY loss is split between these two conditions. On shorter  
 211 timeframes, the model would be more sensitive to assumptions around symptomatic COVID-19  
 212 prevalence and QOL loss as symptomatic COVID-19 is a larger proportion of total QALY loss at shorter  
 213 timeframes.

214 Figure 4: Results of sensitivity analysis on key parameters



215

A model framework for projecting the prevalence and impact of Long-COVID in the UKA model  
framework for projecting the prevalence and impact of Long-COVID in the UK

## 216 Discussion

217 We modelled QALY loss due to COVID-19 symptoms and permanent injury in the UK population. To  
218 the best of our knowledge, this is the first such study on a UK population using UK data. Basu and  
219 Gandhay modelled the QALY impact of averting a single COVID-19 infection in an American setting(24)  
220 and reported QALY loss due to symptomatic (outpatient) COVID-19 of 0.007 (95% CI: 0.002-0.011) per  
221 COVID-19 infection. This compares to our 0.0075 and 0.0135 for 1- and 10-year horizons, respectively.  
222 A further 0.002 QALY loss to family members due to symptomatic COVID-19 and 0.048 QALY due to  
223 COVID-19 deaths was modelled by Basu and Gandhay, both of which was out of our scope. Basu and  
224 Gandhay assumed utility loss for symptomatic outpatients of 0.43 (based on utility of H1N1 patients  
225 on the day of index medical visit), compared to our 0.10, based on COVID-19 symptomatic patients on  
226 average 48 days post-discharge. Given the longer timeframe of our model (including modelled  
227 symptomatic infections), we felt 0.10 is appropriate. In Basu and Gandhay's model, 0.005% of  
228 symptomatic patients recover with permanent kidney injury, while in our model, 0.2% of all infections  
229 resulted in permanent injury.

230 Various studies have reported widely varying estimates of symptom prevalence (Figure 2). At 12  
231 weeks, the Coronavirus Infection Survey (shown as Population) reports a prevalence of any symptoms  
232 of 9.9% but the Arnold study reports a prevalence of 74% (shown as Hospitalised). The Arnold study  
233 sample includes hospitalised patients only whereas the CIS study is population-based. Even when  
234 considering hospitalisation as a risk factor and the different study populations, the prevalence  
235 variation appears larger than expected. The Sudre study (shown as App-users) conducted from a  
236 COVID app reported a lower symptom prevalence of 2.3%. This might reflect sampling and recording  
237 biases as the users were self-selected and responsible for the recording symptoms. The means of  
238 eliciting responses in symptom studies can have a significant impact on the estimated prevalence thus  
239 making comparison between studies difficult (25–27). Symptom prevalence studies are also  
240 complicated by adjusting for background prevalence as well as varying definitions of symptoms.

241 QALYs can be used to estimate disease burden as it is a measure that reflects both the quantity and  
242 quality of life. By integrating the impact of disease on mortality and morbidity into a single index,  
243 comparisons between different diseases can be made. For current modelling purposes, it was the most  
244 appropriate measure to estimate the prevalence and health impact long-COVID due to its  
245 standardised, reproducible and summarised characteristics of HRQoL. However, the effects of COVID-  
246 19 are not limited to health. There are economic impacts to individuals and the country as well as  
247 wellbeing impacts on family members of those symptomatic. Additionally, measures taken to limit the  
248 spread of SARS-Cov-2 impact wellbeing and the overall economy (28).

## 249 Potential implications

### 250 Health and Care Services

251 Proactive care and tailored intervention support will be required in order to locate and accommodate  
252 the needs of these patients in the most appropriate setting. We second the recommendation from  
253 Halpin et al. that rehabilitation services should be planned “to manage these symptoms appropriately  
254 and maximise the functional return of COVID-19 survivors” (15) There will be a lasting health burden  
255 within our society for those who are COVID injured who will require ongoing support. Without  
256 adequate planning this may put further pressures on NHS resources.

257 Prevention is better than cure. We provide these numbers as health economic rationale or a  
258 willingness to pay to avoid an accumulation of injury due to COVID-19. This provides further  
259 justification for the vaccination programme, which has been shown to provide significant reduction in  
260 severe disease outcomes (29,30). Given the socio-economic disparity in the pandemic burden, this

A model framework for projecting the prevalence and impact of Long-COVID in the UKA model  
framework for projecting the prevalence and impact of Long-COVID in the UK

261 may provide justification for spending which seeks to reduce health inequalities such as tailored public  
262 health messaging, vaccination delivery, and community access to care. In addition, this provides  
263 support for non-pharmaceutical interventions that reduce the transmission of the SARS-Cov-2.

#### 264 Societal and economic

265 For the Symptomatic COVID-19 cohort, return to work may be delayed causing increased claims on  
266 statutory sick pay, group employer or individual income protection insurance. For the COVID-injured  
267 cohort, some may not return to fully to work. This may cause increased claims on government  
268 unemployment and disability benefits. Both cohorts would benefit from flexibility in working  
269 arrangements and return to work to better accommodate the individuals' needs and ensure continued  
270 employability.

271 Given the socio-economic disparity in the pandemic burden, there may be a disparity in the economic  
272 impact of permanent injury from COVID-19 which warrants further investigation to prevent a  
273 generational widening of the health inequality gap. Some in society have been, and are, at increased  
274 risk of infection due to their occupation. We agree with the calls for "further research into the role of  
275 repeated exposure to SARS-Cov-2 in a healthcare delivery setting and or in the community, and role  
276 of the repeated exposures leading to autoimmune mediated responses"(31).

#### 277 Limitations

278 The mechanisms of underlying pathogenesis and resulting symptoms of COVID-19 is not yet fully  
279 understood. Although NICE have published a working definition, this may be subject to change. This  
280 model estimates a disease that is evolving and as such, its ability to predict long-term outcomes will  
281 be limited. There is uncertainty around some of the parameters being used in the model and a number  
282 of assumptions had to be made. Survival rates of ward and ITU care were based on 2020 data and  
283 could since have improved as improvements are being made in care for COVID-19 patients. Improved  
284 knowledge on treatment for COVID-19 in wards and ITUs could also reduce the proportion of  
285 permanently injured amongst survivors.

286 The quality of the symptom prevalence data used could be improved by standardising measurement  
287 and recording of symptoms. Currently data is being gathered using different types of questionnaire in  
288 different mediums e.g., Halpin (2020) developed their own COVID-19 rehabilitation telephone  
289 screening tool, Arnold (2020) used the SF-36 questionnaire and Sudre (2020) used a self-reporting  
290 questionnaire via an app. Standardised and validated questionnaires and tools exist and are used to  
291 record patient reported outcomes (PROs). These include the St George's respiratory questionnaire  
292 and the MRC dyspnoea scale (32,33). However, these are often disease-specific and may not be  
293 appropriate for use in long-COVID patients. In addition, HRQoL questionnaires like SF-36 maybe too  
294 general and may not capture all effects resulting from the multiple possible symptoms of COVID-19.

295 The Coronavirus Infection Survey study was used to inform the prevalence of ongoing symptoms from  
296 diagnosis. It was the study with the largest sample and it also reflected the general population  
297 prevalence due to the sampling methods used. Currently, we know the prevalence of ongoing  
298 symptoms up to 12-weeks while the pandemic has lasted for more than 1-year so this is a relatively  
299 short timeframe evidence base. As the survey continues to collect more data, the prevalence figures  
300 could be updated to better reflect long-term outcomes.

301 Our calculation of infections that result in long-COVID uses fatigue as the most common symptom  
302 post-discharge (15). This symptom was used as it was the most commonly reported in the symptom  
303 prevalence studies. However, fatigue is also a commonly reported symptom in the general population  
304 and prevalence varies. One review of fatigue as a symptom in 1992 found prevalence estimates in the

A model framework for projecting the prevalence and impact of Long-COVID in the UKA model  
framework for projecting the prevalence and impact of Long-COVID in the UK

305 general population ranging from 4% to 45% (26). Therefore, when a patient reports ‘fatigue’ it is not  
306 known if the symptom is due to long-COVID or other factors. In addition, the interviewer asks the  
307 interviewee to reference the time of interview and to a pre-COVID state which may result in recall  
308 bias.

309 One of the assumptions of the model is that the average lost QALY rate for symptomatic patients in  
310 shorter durations is similar to the Long-COVID lost QALY rate. This will affect how well the lost QALY  
311 rate estimated by the model reflects the actual HRQoL of long-COVID. Again, as more data is collected  
312 on HRQoL in patients with persistent symptoms, these limitations can be reconciled.

## 313 Conclusion

314 This article describes a model for estimating the health impact of COVID-19 symptoms, including long-  
315 COVID and permanent injury from COVID-19. Quality adjusted life-years lost are used to present a  
316 standardised measure of the impacts and uses the HM Treasury to quantify the impact in monetary  
317 terms. The model framework is presented such that it can be updated with information as more  
318 reliable data accumulates. Based on the current parameterisation, 557,754 QALYs would be lost over  
319 10-years, 286,454 to permanent injury as a result of COVID-19 and 271,300 from symptoms of COVID-  
320 19 across all timescales. An estimated 90,142 people could be left living with significant impairments  
321 as a result of injury from COVID-19.

322 This model framework highlights just some of the factors that will influence the impact of the Long-  
323 COVID burden in our society, our limited understanding of the condition to date, and the limited  
324 information available. There is great uncertainty in the prevalence of symptoms over time as a result  
325 of lack of standardisation in methods used to measure it. Standardised patient report outcomes  
326 instruments need to be used, and there may be a need to develop and validate COVID-19 specific  
327 symptom measures.

## 328 Acknowledgements

329 Many people have supported this work, including:

- 330 • Steve Bale, Senior Actuary, Munich Re
- 331 • Scott Reid, Global Protection Pricing & Product Development Actuary, Zurich Insurance
- 332 • Matt Gurden, Actuarial Director, Government Actuary’s Department
- 333 • Louisa Rutherford, Medical writer, Crystallise
- 334 • Holly Gould, Researcher, Crystallise
- 335 • Hannah Rice, Researcher, Crystallise
- 336 • Walter Rodney Ngumo, Researcher, Crystallise
- 337 • Nicola Clarke, Researcher, Crystallise
- 338 • Christian Todaro, Researcher, Crystallise
- 339 • Colin Dutkiewicz, Global Head of Life, Aon Reinsurance Solutions

340

## 341 References

- 342 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with  
343 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497–506.
- 344 2. World Health Organization. Coronavirus disease (COVID-19) pandemic [Internet]. 2021 [cited  
345 2021 Apr 24]. Available from: [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)  
346 coronavirus-2019

A model framework for projecting the prevalence and impact of Long-COVID in the UKA model  
framework for projecting the prevalence and impact of Long-COVID in the UK

- 347 3. GOV.UK Coronavirus (COVID-19) in the UK [Internet]. 2020 [cited 2020 Dec 22]. Available  
348 from: <https://coronavirus.data.gov.uk/>
- 349 4. NICE, SIGN, RCGP. COVID-19 rapid guideline: managing the long-term effects of COVID-19.  
350 London, Edinburgh; 2020.
- 351 5. Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes  
352 after hospitalisation with COVID-19 and implications for follow-up: results from a prospective  
353 UK cohort. *Thorax* [Internet]. 2020 Dec 3;thoraxjnl-2020-216086. Available from:  
354 <https://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2020-216086>
- 355 6. Fraser E. Long term respiratory complications of covid-19. *BMJ* [Internet]. 2020 Aug 3;m3001.  
356 Available from: <https://www.bmj.com/lookup/doi/10.1136/bmj.m3001>
- 357 7. Kamdar BB, Suri R, Suchyta MR, Digrande KF, Sherwood KD, Colantuoni E, et al. Return to  
358 work after critical illness: a systematic review and meta-analysis. *Thorax* [Internet]. 2020  
359 Jan;75(1):17–27. Available from: [https://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-](https://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2019-213803)  
360 [2019-213803](https://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2019-213803)
- 361 8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of  
362 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*  
363 [Internet]. 2020;6736(20):1–9. Available from: [http://dx.doi.org/10.1016/S0140-](http://dx.doi.org/10.1016/S0140-6736(20)30566-3)  
364 [6736\(20\)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3)
- 365 9. Office for National Statistics. The prevalence of long COVID symptoms and COVID-19  
366 complications [Internet]. 2020 [cited 2021 Jan 19]. Available from:  
367 [https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidssymptomsan](https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidssymptomsandcovid19complications)  
368 [dcovid19complications](https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidssymptomsandcovid19complications)
- 369 10. Herridge MS, Moss M, Hough CL, Hopkins RO, Rice TW, Bienvenu OJ, et al. Recovery and  
370 outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family  
371 caregivers. *Intensive Care Med* [Internet]. 2016 May 30;42(5):725–38. Available from:  
372 <http://link.springer.com/10.1007/s00134-016-4321-8>
- 373 11. Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional  
374 Disability 5 Years after Acute Respiratory Distress Syndrome. *N Engl J Med* [Internet]. 2011  
375 Apr 7;364(14):1293–304. Available from:  
376 <http://www.nejm.org/doi/abs/10.1056/NEJMoa1011802>
- 377 12. Ahmed H, Patel K, Greenwood D, Halpin S, Lewthwaite P, Salawu A, et al. Long-term clinical  
378 outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory  
379 syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review  
380 and meta-analysis. *J Rehabil Med* [Internet]. 2020; Available from:  
381 <https://www.medicaljournals.se/jrm/content/abstract/10.2340/16501977-2694>
- 382 13. McDonald S, Martin C, Bale S, Luteijn M, Sarkar R. Construction of a demand and capacity  
383 model for intensive care and hospital ward beds, and mortality from COVID-19. *MedRxiv*  
384 [Internet]. 2021; Available from:  
385 <https://www.medrxiv.org/content/10.1101/2021.01.06.21249341v1>
- 386 14. Briggs AH, Goldstein DA, Kirwin E, Meacock R, Pandya A, Vanness DJ, et al. Estimating  
387 (quality-adjusted) life-year losses associated with deaths: With application to COVID-19.  
388 *Health Econ* [Internet]. 2021 Mar 24;30(3):699–707. Available from:  
389 <https://onlinelibrary.wiley.com/doi/10.1002/hec.4208>
- 390 15. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms  
391 and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. *J*  
392 *Med Virol* [Internet]. 2021 Feb 17;93(2):1013–22. Available from:  
393 <https://onlinelibrary.wiley.com/doi/10.1002/jmv.26368>
- 394 16. Sudre C, Murray B, Varsavsky T, Graham M, Penfold R, Bowyer R, et al. Attributes and  
395 predictors of Long-COVID: analysis of COVID cases and their symptoms 2 collected by the  
396 Covid Symptoms Study App. *MedRxiv* [Internet]. 2020; Available from:  
397 <https://www.medrxiv.org/content/10.1101/2020.10.19.20214494v2>



A model framework for projecting the prevalence and impact of Long-COVID in the UKA model  
framework for projecting the prevalence and impact of Long-COVID in the UK

- 398 17. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20  
399 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation  
400 Protocol: Prospective observational cohort study. *BMJ*. 2020;369(March):1–12.
- 401 18. ICNARC. ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland 24  
402 December 2020 [Internet]. 2020. Available from: [https://www.icnarc.org/Our-](https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports)  
403 [Audit/Audits/Cmp/Reports](https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports)
- 404 19. COVID-19 Daily Deaths [Internet]. [england.nhs.uk](https://www.england.nhs.uk). [cited 2020 Oct 21]. Available from:  
405 <https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-daily-deaths/>
- 406 20. ONS. Coronavirus (COVID-19) Infection Survey: antibody data for the UK, January 2021  
407 [Internet]. 2021 [cited 2021 Jan 22]. Available from:  
408 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsan](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/antibodydatafortheukjanuary2021)  
409 [ddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/antibodydatafort](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/antibodydatafortheukjanuary2021)  
410 [heukjanuary2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/antibodydatafortheukjanuary2021)
- 411 21. Marti J, Hall P, Hamilton P, Lamb S, McCabe C, Lall R, et al. One-year resource utilisation,  
412 costs and quality of life in patients with acute respiratory distress syndrome (ARDS):  
413 Secondary analysis of a randomised controlled trial. *J Intensive Care* [Internet]. 2016;4(1):1–  
414 11. Available from: <http://dx.doi.org/10.1186/s40560-016-0178-8>
- 415 22. Janssen MF, Szende A, Cabases J, Ramos-Goñi JM, Vilagut G, König HH. Population norms for  
416 the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. *Eur J Heal Econ*  
417 [Internet]. 2019 Mar 14;20(2):205–16. Available from:  
418 <http://link.springer.com/10.1007/s10198-018-0955-5>
- 419 23. HM Treasury. THE GREEN BOOK CENTRAL GOVERNMENT GUIDANCE ON APPRAISAL AND  
420 EVALUATION. London; 2020.
- 421 24. Basu A, Gandhay VJ. Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection  
422 Prevented in the United States. *Value Heal* [Internet]. 2021 Mar; Available from:  
423 <https://linkinghub.elsevier.com/retrieve/pii/S1098301521000346>
- 424 25. Ophuis RH, Olij BF, Polinder S, Haagsma JA. Prevalence of post-traumatic stress disorder,  
425 acute stress disorder and depression following violence related injury treated at the  
426 emergency department: a systematic review. *BMC Psychiatry* [Internet]. 2018 Dec  
427 25;18(1):311. Available from:  
428 <https://bmcp psychiatry.biomedcentral.com/articles/10.1186/s12888-018-1890-9>
- 429 26. Carlson KF, Kehle SM, Meis LA, Greer N, MacDonald R, Rutks I, et al. Prevalence, Assessment,  
430 and Treatment of Mild Traumatic Brain Injury and Posttraumatic Stress Disorder. *J Head*  
431 *Trauma Rehabil* [Internet]. 2011;26(2):103–15. Available from:  
432 <http://journals.lww.com/00001199-201103000-00001>
- 433 27. Lewis G, Wessely S. The epidemiology of fatigue: more questions than answers. *J Epidemiol*  
434 *Community Heal* [Internet]. 1992 Apr 1;46(2):92–7. Available from:  
435 <https://jech.bmj.com/lookup/doi/10.1136/jech.46.2.92>
- 436 28. Zala D, Mosweu I, Critchlow S, Romeo R, McCrone P. Costing the COVID-19 Pandemic: An  
437 Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom.  
438 *Value Heal* [Internet]. 2020 Nov;23(11):1432–7. Available from:  
439 <https://linkinghub.elsevier.com/retrieve/pii/S1098301520322075>
- 440 29. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety  
441 and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in  
442 young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet*  
443 [Internet]. 2020 Dec;396(10267):1979–93. Available from:  
444 <https://linkinghub.elsevier.com/retrieve/pii/S0140673620324661>
- 445 30. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the  
446 mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* [Internet]. 2021 Feb 4;384(5):403–16.  
447 Available from: <http://www.nejm.org/doi/10.1056/NEJMoa2035389>
- 448 31. Alwan NA, Attree E, Blair JM, Bogaert D, Bowen M-A, Boyle J, et al. From doctors as patients:

A model framework for projecting the prevalence and impact of Long-COVID in the UKA model  
framework for projecting the prevalence and impact of Long-COVID in the UK

- 449 a manifesto for tackling persisting symptoms of covid-19. BMJ [Internet]. 2020 Sep 15;m3565.  
450 Available from: <https://www.bmj.com/lookup/doi/10.1136/bmj.m3565>  
451 32. Littlejohns P, Ebrahim S, Anderson R. Prevalence and diagnosis of chronic respiratory  
452 symptoms in adults. Br Med J [Internet]. 1989;298(6687):1556–60. Available from:  
453 [https://rsm.idm.oclc.org/login?url=https://www.rsm.ac.uk?url=https://dialog.proquest.com/](https://rsm.idm.oclc.org/login?url=https://www.rsm.ac.uk?url=https://dialog.proquest.com/professional/docview/701275003?accountid=138535)  
454 [professional/docview/701275003?accountid=138535](https://rsm.idm.oclc.org/login?url=https://www.rsm.ac.uk?url=https://dialog.proquest.com/professional/docview/701275003?accountid=138535)  
455 33. Mahler DA, Wells CK. Evaluation of Clinical Methods for Rating Dyspnea. Chest [Internet].  
456 1988 Mar;93(3):580–6. Available from:  
457 <https://linkinghub.elsevier.com/retrieve/pii/S001236921630335X>  
458